Related Experiment Videos
Reduction in plasma norepinephrine during fenfluramine treatment.
Clinical Pharmacology and Therapeutics
|February 1, 1977
Summary
Fenfluramine significantly reduced plasma norepinephrine and dopamine beta-hydroxylase activity. This suggests potential antiadrenergic effects for treating conditions involving circulating catecholamines.
Area of Science:
- Pharmacology
- Neuroscience
- Biochemistry
Background:
- Circulating catecholamines play a role in various physiological and pathological processes.
- Understanding the regulation of catecholamine levels is crucial for developing therapeutic strategies.
Purpose of the Study:
- To investigate the effects of chronic fenfluramine administration on plasma catecholamine levels.
- To assess the impact of fenfluramine on dopamine beta-hydroxylase activity.
Main Methods:
- Administration of fenfluramine (120 mg/day) for at least 10 days.
- Measurement of plasma norepinephrine levels.
- Assay of plasma dopamine beta-hydroxylase activity.
Main Results:
- Fenfluramine treatment reduced plasma norepinephrine levels to 30% of placebo levels.
- A significant reduction in plasma dopamine beta-hydroxylase activity was observed during fenfluramine treatment.
Conclusions:
- Chronic fenfluramine administration exhibits antiadrenergic effects.
- These findings suggest fenfluramine's potential utility in managing disorders associated with elevated circulating catecholamines.